We are live on ! Find out more
CLVS

Clovis Oncology, Inc.

Delisted

CLVS was delisted on the 20th of December, 2022.

138 hedge funds and large institutions have $1.31B invested in Clovis Oncology, Inc. in 2014 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 58 increasing their positions, 38 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more funds holding in top 10

Funds holding in top 10: 47 (+3)

53% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 38

26% more call options, than puts

Call options by funds: $31M | Put options by funds: $24.6M

13% more capital invested

Capital invested by funds: $1.16B → $1.31B (+$147M)

8% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 25

1% less funds holding

Funds holding: 140138 (-2)

Holders
138
Holders Change
-2
Holders Change %
-1.43%
% of All Funds
4%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.2%
New
23
Increased
58
Reduced
38
Closed
25
Calls
$31M
Puts
$24.6M
Net Calls
+$6.38M
Net Calls Change
+$17.3M
Name Holding Trade Value Shares
Change
Change in
Stake
VOYA Investment Management
26
VOYA Investment Management
Georgia
$11.7M +$2.09M +50,062 +24%
FCM
27
Farallon Capital Management
California
$10.2M
Citadel Advisors
28
Citadel Advisors
Florida
$9.3M +$8.15M +195,069 +1,952%
CCI
29
Columbus Circle Investors
$8.63M +$5.39M +129,068 +211%
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$8.01M -$7.62M -182,521 -51%
Millennium Management
31
Millennium Management
New York
$7.88M +$4.61M +110,402 +175%
Geode Capital Management
32
Geode Capital Management
Massachusetts
$7.6M +$191K +4,579 +3%
Balyasny Asset Management
33
Balyasny Asset Management
Illinois
$7.54M +$4.2M +100,533 +153%
Invesco
34
Invesco
Georgia
$6.93M +$416K +9,964 +7%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$6.26M +$215K +5,151 +4%
OM
36
Opaleye Management
Massachusetts
$6.21M +$418K +10,000 +8%
Morgan Stanley
37
Morgan Stanley
New York
$5.84M +$3.93M +94,161 +273%
CS
38
Credit Suisse
Switzerland
$5.74M +$149K +3,563 +3%
TCIM
39
TIAA CREF Investment Management
New York
$5.73M -$76.6K -1,834 -1%
CC
40
CQS Cayman
Cayman Islands
$5.67M +$5.22M +125,000 New
U
41
UBS
Switzerland
$5.51M +$2.86M +68,356 +128%
Norges Bank
42
Norges Bank
Norway
$4.89M -$10.3M -246,223 -70%
TCM
43
Tekla Capital Management
Massachusetts
$4.72M +$2.37M +56,687 +120%
SFM
44
Sphera Funds Management
Israel
$4.63M -$127K -3,045 -3%
CM
45
Corvex Management
New York
$4.25M +$3.91M +93,586 New
BIM
46
BlackRock Investment Management
Delaware
$3.92M +$795K +19,032 +28%
GC
47
Guggenheim Capital
Illinois
$3.86M +$112K +2,686 +3%
Deutsche Bank
48
Deutsche Bank
Germany
$3.8M +$168K +4,032 +5%
Charles Schwab
49
Charles Schwab
California
$3.37M +$219K +5,233 +8%
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$3.25M -$2.17M -51,829 -42%

CLVS Hedge Fund Activity: Q3 2014 in Review

138 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2014, worth a combined $1.31B — up 13% from $1.16B a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of CLVS and 23 opened new positions — a net loss of 2 holders — while 38 trimmed existing stakes and 58 added.

The largest buyer was PFM Health Sciences, adding an estimated $34.5M. The largest seller was Fidelity Investments, cutting an estimated $46.5M.

  • 138 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q3 2014, down from 140 in Q2 2014.
  • Funds reported $1.31B of Clovis Oncology, Inc. stock for Q3 2014, up 13% quarter-over-quarter.
  • 23 funds opened new Clovis Oncology, Inc. positions in Q3 2014 and 25 closed out, a net change of -2 holders.
  • The largest Clovis Oncology, Inc. buyer in Q3 2014 was PFM Health Sciences, an estimated $34.5M added.
  • The largest Clovis Oncology, Inc. seller in Q3 2014 was Fidelity Investments, an estimated $46.5M sold.

Based on aggregated 13F filings for Q3 2014.